Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
23ME-00610 in advanced solid malignancies
NCT05199272Phase 2Active, not recruiting
- Sponsor
- 23andMe
- Start
- Dec 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of 23ME-00610 in solid tumor (advanced stage), clear cell renal cell carcinoma (ccRCC), Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by 23andMe. Started Dec 2021; status: active, not recruiting.
02
Drugs
23ME-00610
03
Conditions
solid tumor (advanced stage)clear cell renal cell carcinoma (ccRCC)Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05199272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199272.